Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.53 |
| ▸ | GRM5 | P41594 | 9/20 | 0.53 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.48 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29227506 | 1.00 | NAMPT (0.60) | NAMPTPDK4NR1H2GRM1GRM5 | |
| Carbamic Acid SCHEMBL31489255 | 0.96 | NAMPT (0.57) | NAMPTPDK4NR1H2GRM1GRM5 | |
| SCHEMBL25233965 | 0.92 | NAMPT (0.53) | NAMPTPDK4NR1H2GRM1GRM5 | |
| SCHEMBL8912847 | 0.89 | NAMPT (0.63) | NAMPTPDK4GRM1GRM5TNK2 | |
| SCHEMBL904049 | 0.88 | NAMPT (0.61) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL17002448 | 0.88 | NR1H2 (0.52) | NAMPTPDK4NR1H2GRM1GRM5 | |
| SCHEMBL30778341 | 0.87 | NAMPT (0.56) | NAMPTPDK4NR1H2GRM1GRM5 | |
| SCHEMBL15157008 | 0.87 | NAMPT (0.56) | NAMPTPDK4NR1H2GRM1GRM5 | |
| SCHEMBL29227507 | 0.87 | NAMPT (0.49) | NAMPTPDK4NR1H2GRM1GRM5 | |
| SCHEMBL31110456 | 0.87 | NAMPT (0.58) | NAMPTPDK4GRM1GRM5TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072437-A1 | HETEROARYL COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ALPHINA THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250082762-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-03-13 | — | — | US | disclosed |
| US-20250073341-A1 | BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-03-06 | — | — | US | disclosed |
| US-12161722-B2 | Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-12-10 | — | — | US | disclosed |
| CN-118743770-A | Positron Emission Tomography (PET) radiotracer for imaging macrophage colony stimulating factor 1 receptor (CSF 1R) in neuroinflammation | 约翰霍普金斯大学 | 2024-10-08 | — | — | CN | disclosed |
| US-20240308994-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2024-09-19 | — | — | US | disclosed |
| US-20240285778-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-29 | — | — | US | disclosed |
| EP-4361153-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-05-01 | — | — | EP | disclosed |
| CN-113614087-B | WEE1 inhibitor and preparation and application thereof | 首药控股(北京)股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2023096304-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | 한양대학교 에리카산학협력단 | 2023-06-01 | — | — | WO | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | US | disclosed |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | US | disclosed |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | US | disclosed |
| WO-2006138155-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060189623-A1 | Inhibitors of c-fms kinase | ILLIG CARL R | 2006-08-24 | — | — | US | disclosed |
| US-20060148812-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189623-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | NAMPT 2502/4885PDK4 2546/4885NR1H2 3829/4885 |
| US-20250073341-A1 | BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | BTK, XIAP, SYK | NAMPT 3067/4885PDK4 2458/4885NR1H2 4272/4885 |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | NAMPT 665/4885PDK4 2317/4885NR1H2 271/4885 |
| US-20250082762-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | BTK, XIAP, UBE3C | NAMPT 3168/4885PDK4 2276/4885NR1H2 4249/4885 |
| US-20060148812-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | NAMPT 2502/4885PDK4 2546/4885NR1H2 3829/4885 |
| US-12161722-B2 | Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof | BTK, XIAP, SYK | NAMPT 3067/4885PDK4 2458/4885NR1H2 4272/4885 |
| US-20240285778-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | BTK, XIAP, UBE3C | NAMPT 3168/4885PDK4 2276/4885NR1H2 4249/4885 |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | FLT3, FES, FGR | NAMPT 2198/4885PDK4 1980/4885NR1H2 4232/4885 |
| US-20240308994-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | CSF1R, CSF3R, IL15RA | NAMPT 2030/4885PDK4 963/4885NR1H2 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.